Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study

Journal of Physiology and Pharmacology

Volumn 66, Issue 1, 2015, Pages 111-128

  Mroz, Robert M ^a   Lisowski, P ^b,c   Tycinska, A ^a   Bierla, J ^d   Trzeciak, P Z ^e   Minarowski, L ^a   Milewski, R ^a   Lisowska, A ^a   Boros, P ^f   Sobkowicz, B ^a   Duszewska, A M ^e   Chyczewska, E ^a   Musial, W J ^a   MacNee, W ^g  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^f NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Atorvastatin; Chronic obstructive lung disease; Immunohistochemistry; Lung volumes; Statins; Transcriptome profiling

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CARBON MONOXIDE; CD45 ANTIGEN; CHOLESTEROL ESTER; CREATINE KINASE ISOENZYME; TRANSCRIPTOME; ANTIINFECTIVE AGENT; AUTACOID; GENETIC MARKER;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOPSY; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL COUNT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; RESPIRATORY TRACT PARAMETERS; SIGNAL TRANSDUCTION; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TISSUE MICROARRAY; TREATMENT OUTCOME; AGED; CONVALESCENCE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; IMMUNOLOGY; LUNG; LUNG FUNCTION TEST; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; POLAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; TIME;

AGED; ANTI-INFECTIVE AGENTS; ATORVASTATIN CALCIUM; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; LUNG; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PILOT PROJECTS; POLAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923118382     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C.
2. Gordon DJ, Rifkind BM. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents. Ann Intern Med. 1987; 107: 759-761.
3. Faggiotto A, Paoletti R. State-of-the-art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-996.
4. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-217.
5. Korybalska K, Kawka E, Breborowicz A, Witowski J. Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury. J Physiol Pharmacol 2012; 63: 389-395.
6. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004; 117: 596-606.
7. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-2056.
8. Gurm HS, Hoogwerf B. The Heart Protection Study: highrisk patients benefit from statins, regardless of LDL-C level. Cleve Clin J Med 2003;70:991-997.
9. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009; 136: 734-743.
10. van Eijl S, Mortaz E, Versluis C, Nijkamp FP, Folkerts G, Bloksma N. A low vitamin A status increases the susceptibility to cigarette smoke-induced lung emphysema in C57BL/6J mice. J Physiol Pharmacol 2011; 62: 175-182.
11. Mikolka P, Mokra D, Drgova A, Petras M, Mokry J. Dimethyl sulfoxide in a 10% concentration has no effect on oxidation stress induced by ovalbumin-sensitization in a guinea-pig model of allergic asthma. J Physiol Pharmacol 2012; 63: 179-186.
12. Sharman JE, Johns DP, Marrone J, Walls J, Wood-Baker R, Walters EH. Cardiovascular effects of methacholine-induced airway obstruction in man. J Physiol Pharmacol 2014; 65: 401-407.
13. Chen YJ, Chen P, Wang HX, et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int Immunopharmacol 2010; 10: 685-693.
14. Arimura K, Aoshiba K, Tsuji T, Tamaoki J. Chronic lowgrade systemic inflammation causes DNA damage in the lungs of mice. Lung 2012; 190: 613-620.
15. Miyata R, Bai N, Vincent R, Sin DD, Van Eeden SF. Statins reduce ambient particulate matter-induced lung inflammation by promoting the clearance of particulate matter, < 10 μm from lung tissues. Chest 2013; 143: 452-460.
16. Davis BB, Zeki AA, Bratt JM, Wang L, Filosto S, Walby WF, et al. Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respiratory J 2013; 42: 350-361.
17. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
18. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005; 26: 153-161.
19. Holownia A, Mroz R, Noparlik J, Chyczewska E, Braszko J. Expression of CREB-binding protein and peroxisome proliferator-activated receptor gamma during formoterol or formoterol and corticosteroid therapy of chronic obstructive pulmonary disease. J Physiol Pharmacol 2008; 59 (Suppl. 6): 303-309.
20. Guidelines for fiberoptic bronchoscopy in adults. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1987; 136: 1066.
21. British Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of Standards of Care Committee of British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001; 56 (Suppl. 1): i1-i21.
22. Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123: 1693-1717.
23. Lisowski P, Stankiewicz AM, Goscik J, et al. Effects of chronic stress on prefrontal cortex transcriptome in micedisplaying different genetic backgrounds. J Mol Neurosci 2013; 50: 33-57.
24. Lisowski P, Stankiewicz AM, Goscik J, Wieczorek M, Zwierzchowski L, Swiergiel AH. Selection for stressinduced analgesia affects the mouse hippocampal transcriptome. J Mol Neurosci 2012; 47: 101-112.
25. Lisowski P, Juszczak GR, Goscik J, Wieczorek M, Zwierzchowski L, Swiergiel AH. Effect of chronic mild stress on hippocampal transcriptome in mice selected for high and low stress-induced analgesia and displaying different emotional behaviors. Eur Neuropsychopharmacol 2011; 21: 45-62.
26. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818.
27. Cazzola M, Matera M, Rogliani P, Page C. Treating systemic effects of COPD. Trends Pharmacol Sci 2007; 28: 544-550.
28. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009; 18: 222-232.
29. Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir 2012; 12: 35-40.
30. Braganza G, Chaudhuri R, McSharry C, et al. Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulm Med 2011; 11: 16.
31. Marin L, Colombo P, Bebawy M, Young PM, Traini D. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv 2011; 8: 1205-1220.
32. Reed RM, Iacono A, DeFilippis A, et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD 2011; 8: 96-102.
33. Kaczmarek P, Sladek K, Skucha W, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 2010; 120: 11-17.
34. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-993.
35. Le NT, Takei Y, Izawa-Ishizawa Y, et al. Identification of activators of ERK5 transcriptional activity by highthroughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J Immunol 2014; 193: 3803-3815.
36. Zhang S, Rahman M, Zhang S, Jeppsson B, Herwald H, Thorlacius H. Streptococcal m1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration of the lungs. Infect Immun 2012; 80: 3952-3959.
37. Golpon HA, Coldren CD, Zamora MR, et al. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol 2004; 31: 595-600.
38. Ning W, Lee J, Kaminski N, et al. Comprehensive analysis of gene expression on GOLD-2 versus GOLD-0 smokers reveals novel genes important in the pathogenesis of COPD. Proc Am Thorac Soc 2006; 3: 466.
39. Zeskind JE, Lenburg ME, Spira A. Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. Proc Am Thorac Soc 2008; 5: 834-841.
40. Wang IM, Stepaniants S, Boie Y, et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008; 177: 402-411.
41. Bhattacharya S, Tyagi S, Srisuma S, et al. Peripheral blood gene expression profiles in COPD subjects. J Clin Bioinforma 2011; 1: 12. doi: 10.1186/2043-9113-1-12.
42. Hersh CP, DeMeo DL, Raby BA, et al. Genetic linkage and association analysis of COPD-related traits on chromosome 8p. COPD 2006; 3: 189-194.
43. Spira A, Beane J, Pinto-Plata V, et al. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am JRespir Cell Mol Biol 2004; 31: 601-610.
44. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
45. Silverman EK. Genetic epidemiology of COPD. Chest 2002; 121 (Suppl. 3): 1S-6S.
46. Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, Gamble GD. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008; 32: 1158-1164.